Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy
The efficacy of traditional chemotherapy often suffers from rapid clearance and off-target toxicity. Drug delivery systems and controlled release are applied to improve the therapeutic efficiencies of small-molecule drugs. In this work, two novel oxidative/reductive (Ox/Re) -sensitive and one non-se...
Saved in:
Main Authors: | Jincheng Yang (Author), Qingzhi Lv (Author), Wei Wei (Author), Zhengtao Yang (Author), Jiajun Dong (Author), Ruoshi Zhang (Author), Qiming Kan (Author), Zhonggui He (Author), Youjun Xu (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy
by: Xianbin Ma, et al.
Published: (2022) -
Pure redox-sensitive paclitaxel-maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency
by: Xinyu Lou, et al.
Published: (2021) -
Cancer-targeted design of bioresponsive prodrug with enhanced cellular uptake to achieve precise cancer therapy
by: Yuanwei Liang, et al.
Published: (2018) -
Pheophorbide A and Paclitaxel Bioresponsive Nanoparticles as Double-Punch Platform for Cancer Therapy
by: Francesca Moret, et al.
Published: (2021) -
A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates
by: Yixin Sun, et al.
Published: (2019)